AstraZeneca may sell rights to some future income to boost defenses, FT says

AstraZeneca (AZN) is working with bankers to explore the sale of future income streams from some of its existing drugs as a way to raise "billions of dollars in cash" and boost its defenses against any renewed takeover bid from Pfizer (PFE), said Financial Times, citing people familiar with the matter.

Advertisement